Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

See the latest Gilead Sciences GILD stock price (NASDAQ: GILD), related news, valuation, dividends and more to help you make your investing decisions.

Shares of Gilead Sciences Inc. rallied 2.83% to $110.67 Friday, on what proved to be an all-around great trading session for ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

(Reuters) -Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal mandate that requires health ...

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

Gilead Sciences Inc. closed 11.48% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences - Born With HIV in the 80s: Kim's Story of Growing Up as a Dandelion. NORTHAMPTON, MA / ACCESS Newswire / June 24, 2025 / Kim Canady was only nine years old in 1996 when she faced ...

Gilead Sciences and Kymera Therapeutics have entered into a partnership worth as much as $750m to develop a molecular glue ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...